Stem-cell therapy
iPSC- and ESC-derived dopaminergic cell-transplantation programmes and early-phase trials.
State of the art
No update yet for Stem-cell therapy. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Cellular Intelligence acquires global rights to STEM-PD program
Cellular Intelligence has acquired global rights to STEM-PD from Novo Nordisk and will use an AI platform to advance the program. The Phase 1/2 trial (NCT05635409) has dosed eight participants across UK and Swedish sites, with positive early safety data in the first four patients allowing progression to a higher-dose cohort; the FDA has cleared the program for Phase 2 and granted it Fast Track designation. -
Cell Replacement Approval in Japan and Other Cell Therapy Updates
The video discusses the recent regulatory approval of stem cell therapy in Japan and outlines the current state of global clinical trials aimed at replacing dopamine-producing cells in the brain.